GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG (1999)
    Copenhagen : Munksgaard International Publishers
    Allergy 54 (1999), S. 0 
    Details
    ISSN: 1398-9995
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Background: Cutaneous heparin-induced allergic reactions to subcutaneous heparin may begin 2–5 days after administration. The relation of the delayed-type hypersensitivity and a systemic immunologic response is controversial. The present investigation aimed to analyze the occurrence of thromboembolic complication, pathologic heparin-induced platelet activation (HIPA), and the presence of circulating heparin-induced IgG in patients with heparin-induced skin reactions. Methods: Intracutaneous tests, HIPA assay, and heparin-heparin IgG antibodies were performed in nine patients with heparin-induced skin lesions. Results: Six of eight patients showed positive intracutaneous tests to heparin and to four low-molecular-weight heparins. Three of six heparin-positive patients presented hypersensitivity to a heparinoid, too. Two of three patients had a positive HIPA test and elevated heparin-induced IgG antibodies. Both patients developed complications presenting as heparin-induced skin necrosis or arterial thrombosis. Two of nine patients were treated with danaparoid, 4/9 patients received r-hirudin, and 1/9 received oral coumarin. In 2/9 patients, anticoagulant therapy was stopped, but these patients will receive r-hirudin if indicated. Conclusions: On the basis of the coincidence of local and systemic hyperreactivity to heparin and danaparoid, patients with heparin-induced skin lesions should receive r-hirudin, a nonheparin compound, for anticoagulant treatment.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1034/j.1398-9995.1999.00048.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Characterization of heparins by high-performance size exclusion liquid chromatography
    Amsterdam : Elsevier
    Journal of Chromatography A 261 (1983), S. 287-292 
    Details
    ISSN: 0021-9673
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://linkinghub.elsevier.com/retrieve/pii/S0021-9673(01)87952-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Identification of phenprocoumon metabolites in human urine by high-performance liquid chromatography and gas chromatography-mass spectrometry
    Amsterdam : Elsevier
    Journal of Chromatography B: Biomedical Sciences and Applications 338 (1985), S. 325-334 
    Details
    ISSN: 0378-4347
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://linkinghub.elsevier.com/retrieve/pii/0378-4347(85)80103-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Determination of the anticoagulant phenprocoumon in human plasma and urine by high-performance liquid chromatography
    Amsterdam : Elsevier
    Journal of Chromatography B: Biomedical Sciences and Applications 231 (1982), S. 83-92 
    Details
    ISSN: 0378-4347
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://linkinghub.elsevier.com/retrieve/pii/S0378-4347(00)80511-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Urokinase therapy of subclavian-axillary vein thrombosis (1981)
    Springer
    Journal of molecular medicine 59 (1981), S. 851-856 
    Details
    ISSN: 1432-1440
    Keywords: Subclavian-axillary vein thrombosis ; Thrombosis ; Urokinase ; Fibrinolysis ; Achselvenenthrombose ; Thrombose ; Urokinase ; Fibrinolyse
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei 18 Patienten mit einer Achselvenenthrombose wurde eine fibrinolytische Therapie mit Urokinase in Kombination mit Heparin durchgeführt. Der thrombolytische Effekt war dabei eindeutig vom Alter der Thrombose und der Höhe der Urokinasedosis abhängig. Unter Gabe einer anfänglichen Erhaltungsdosis von 1000–2000 IE/kg/h (Initialdosis 150 000–250 000 IE Urokinase) in Kombination mit Heparin (15–17 E/kg/h) konnte bei neun der 11 Patienten (82%) mit frischen Thrombosen ein nahezu kompletter Behandlungserfolg erzielt werden. Bei einem Thrombusalter von mehr als 10 Tagen war keine phlebographische Befundänderung nachweisbar. Wesentliche Nebenwirkungen wurden nicht beobachtet. Auf Grund der hier mitgeteilten Behandlungsergebnisse sollte bei frischen Thrombosen der V. subclavia oder axillaris eine thrombolytische Therapie mit Urokinase durchgeführt werden. Der hier vorgelegte Erfahrungsbericht erlaubt darüber hinaus generelle Rückschlüsse zur Dosierung und Wirksamkeit der fibrinolytischen Substanz Urokinase.
    Notes: Summary In 18 cases with primary subclavian-axillary vein thrombosis fibrinolytic therapy was performed with urokinase in combination with heparin. The thrombolytic efficacy clearly depended on the thrombus age and the dose of urokinase applied. Under treatment with a median initial maintenance dosage of urokinase of 1,000–2,000 IU/kg/h (loading dose 150,000–250,000 IU urokinase) in combination with heparin (15–17 U kg/h) in nine of 11 patients (82%) with recently developed (8 days or less) thrombosis, a nearly complete deobliteration of the venous system was observed. In the cases with thrombosis of more than 10 days no alteration of the venous occlusions could be seen. Relevant side effects did not occur. Our results emphasize urokinase therapy of acute subclavian-axillary vein thrombosis and permit general inferences concerning the efficacy and the dosage requirements of the thrombolytic substance urokinase.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01721055
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Neutralisierung von niedermolekularem Heparin Kabi 2165 mit Protaminchlorid (1986)
    Springer
    Journal of molecular medicine 64 (1986), S. 1171-1175 
    Details
    ISSN: 1432-1440
    Keywords: Heparin ; Low molecular weight heparin ; Protamine chloride ; Antidot ; Factor XA
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Low molecular weight (LMW) heparin Kabi 2165 possesses improved pharmacodynamic properties compared with conventional heparin. It is currently investigated in the prophylaxis of thromboembolism. The neutralization of Kabi 2165 by protamine chloride was analysed after i.v. injection of both the agent and the antidot in healthy persons. The anticoagulant effects of the LMW heparin on the activated partial thromboplastin time, thrombin, and thromboelastography are completely and immediately suppressed by protamine chloride. The inhibition of factor X a is antagonized up to 50%–60%. The bleeding time remained unaffected. The data indicate that protamine chloride may be used in clinical situations as an antidot to the LMW heparin Kabi 2165. A rebound phenomenon of the anticoagulant effect does not occur.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01728455
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Ambulante Langzeitprophylaxe der Thromboembolie mit niedermolekularem Heparin (1987)
    Springer
    Journal of molecular medicine 65 (1987), S. 331-337 
    Details
    ISSN: 1432-1440
    Keywords: Thromboembolism-prophylaxis ; Bleeding complications ; Oral anticoagulants ; Heparin ; Low molecular weight heparin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Patients with severe bleeding complications and other side effects on conventional anticoagulants and strong indication for further anticoagulation were treated with a low molecular weight heparin fragment (Tedelparin). In this paper we report the experiences in 30 patients, who were anticoagulated 1–11 months with this compound. All patients injected themselves a dose ranging from 1 × 2,500 to 1 × 20,000 anti factor Xa units per day. Within 132 months of treatment one patient with good compliance developed thromboembolism. Four patients had bad compliance. Two of them experienced rethrombosis 1 and 8 weeks after starting therapy. Severe haemorrhages did not occur. Two patients had one minor bleeding complication each. Both patients developed several times per year severe haemorrhages with conventional anticoagulants. All excessive subcutaneous haematomas and indurations of the adipose tissue at the injection site of conventional heparin disappeared completely. Low molecular weight heparin can be regarded as an alternative anticoagulant in patients with severe bleeding and other complications on oral anticoagulants and conventional heparin.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01745389
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Die intraindividuelle Streuung der fibrinolytischen Aktivität bei Probanden (1978)
    Springer
    Journal of molecular medicine 56 (1978), S. 445-448 
    Details
    ISSN: 1432-1440
    Keywords: Fibrinolysis ; Circadian rhythms ; Clinical trial ; Euglobulinlysis-time ; Fibrinolyse ; circadiane Rhythmik ; klinische Prüfung ; Euglobulinlyse-Zeit
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei 5 Probanden wurde über einen Zeitraum von 6 Wochen fünfmal die Anstiegsphase im Tagesrhythmus der fibrinolytischen Aktivität untersucht. Als Parameter wurden die Euglobulinlyse-Zeit und die Papierfibrinolyse, die Plasmaproteine, Fibrinogen, Plasminogen, α1-Antitrypsin und α2-Makroglobulin sowie die Thrombinocoagulase-Zeit und die Fibrinspaltprodukte erfaßt. Es zeigte sich bei allen Probanden der Anstieg der Fibrinolyse am Vormittag. Die Schwankungsbreite der fibrinolytischen Aktivität ist intraindividuell kleiner als bei einem interindividuellen Vergleich. Weiterhin zeigt sie mittags eine geringere Streuung als vormittags. Bei Untersuchungen zur klinischen Prüfung eines Soforteffektes von Arzneimitteln auf die Fibrinolyse sollte der Zeitraum der Plateauphase der fibrinolytischen Aktivität gewählt werden, um die Streuung der Ausgangswerte möglichst gering zu halten. Weiterhin ist die intraindividuelle Streuung der fibrinolytischen Aktivität in diesem Zeitraum geringer als während der Anstiegsphase im Rahmen des circadianen Rhythmus der Fibrinolyse. Eine intraindividuelle Kontrolle muß gewährleistet werden.
    Notes: Summary In five volunteers fibrinolytic activity has been measured five times over a period of six weeks during increasing values of circadian rhythm. Euglobulinlysis-time, paper fibrinolysis, fibrinogen, plasminogen, α1-antitrypsin, α2-makroglobulin, thrombinocoagulase-time and fibrin-split-products were used in one study. An increase of fibrinolytic activity in the mooning was observed in all volunteers. Intraindividual variation of values is considerable but less than variation of values compared interindividually. Moreover variation was smaller at noon than in the time before noon. In clinical trial of the short-time effect of drugs the period of the plateau of the fibrinolytic activity should be used because of its smaller variation of values. Furthermore, in this period the intraindividual variation of the fibrinolytic activity is smaller than during increasing slope of the circadian rhythm of fibrinolysis. Intraindividual control should be granted.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01477058
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Synthesis of a N'-Alkylamine Anticoagulant Active Low-Molecular-Mass Heparin for Radioactive and Fluorescent Labeling
    Amsterdam : Elsevier
    Analytical Biochemistry 217 (1994), S. 255-264 
    Details
    ISSN: 0003-2697
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1006/abio.1994.1117
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Lack of effect of cimetidine on action of phenprocoumon (1982)
    Springer
    European journal of clinical pharmacology 23 (1982), S. 365-367 
    Details
    ISSN: 1432-1041
    Keywords: cimetidine ; phenprocoumon ; warfarine ; drug metabolism interaction ; histamine receptor antagonist ; anticoagulation ; bleeding complication
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary In patients on oral warfarin, nicoumalone and phenindione an increase in the anticoagulant effect has been described during concomitant treatment with cimetidine. Therefore the effect of cimetidine on the steady state dynamics of phenprocoumon has been investigated in ten outpatients. No change in the anticoagulant effect of phenprocoumon was observed during or after two weeks on cimetidine, as measured by the thrombotest coagulation method, prothrombin time, fibrinopeptide A concentration and plasma phenprocoumon level. The data show that cimetidine does not interact with the metabolism of phenprocoumon in contrast to warfarin. Thus, phenprocoumon maintenance therapy when combined with concomitant cimetidine treatment can be considered not to carry an increased risk of haemorrhagic complications.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00613622
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...